UBS Maintains Neutral on Insulet, Lowers Price Target to $150

Benzinga Newsdesk www.benzinga.com Negative 88.3%

Neg 88.3% Neu 0% Pos 0%

UBS analyst Patrick Wood maintains Insulet (NASDAQ:PODD) with a Neutral and lowers the price target from $174 to $150.

Comments

No comments yet. Be the first!